- Birck MG, Lukusa L, Singh H, Afif W, Narula N, Leung Y, Bernatsky. Treatment discontinuation for biosimilar versus orginicator in infliximab. United European Gastroenterology Week (UEG Week), Copenhagen, Denmark, October 14-17, 2023. Submitted.
- Birck MG, Lukusa L, Afif W, Lakatos PL, Bessissow T, Singh H, Oketola B, Narula N, Leung Y, Bernatsky S. Time to first remission and prevalence of sustained remission in inflammatory bowel disease: comparison between infliximab biosimilar or originator. Digestive Disease Week (DDW 2023), Chicago, Illinois, May 6-9, 2023. Abstract E3857065, Poster Presentation.
- Moura CS, Lukusa L, Wong EC, Lakatos PL, Afif W, Narula N, Bernatsky S. Comparison of discontinuation/switching between infliximab biosimilar and originator among inflammatory bowel disease patients: a real-world analysis of two Canadian cohorts. 17th Congress of the European Crohn’s and Colitis Organisation (ECCO), Vienna, Austria, February 16-19, 2022. Abstract EC-22-1562, Poster Presentation.
We are excited to share the first publication from the Canadian IBD Research Consortium: REMIT-UC was a multicenter cohort study looking at real-world effectiveness and safety of tofacitinib in ulcerative colitis. Many thanks to all the participating CIRC sites. This is just the first of many CIRC studies to come!
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn’s disease: A Canadian multi-center study
Clinical practice guidelines recommend ustekinumab as a first-line biological treatment option for moderately-to-severely active Crohn’s disease (CD). However, there is limited real-world effectiveness and safety data in bio-naïve patients. This study aims to assess ustekinumab effectiveness and safety in bio-naïve CD patients.